亚日韩在线中文字幕亚洲,国产在线播放鲁啊鲁视频,张柏芝手扒性器全部图片,亚洲成无码电影在线观看

Proteus mirabilis Hauser 拉丁名

(ATCC® BAA-2792™)  統(tǒng)一編號(hào) 

Reports Upon your purchase of this product, you will receive a report containing MIC values, a susceptibility profile, and the DNA sequence information for predicted annotated antibiotic resistance genes and 16S rRNA genes. This report will be provided in multiple formats (.pdf, .txt, .xls, .zip). 

Deposited As Proteus mirabilis 

Strain Designations 菌種別名 1104843 

Application 用途 Drug discovery and development Development of molecular-based detection assays Development of updated sterility protocols 

Isolation 分離源 Urine Isolation Date 2014 Geographic Source Greece 

Biosafety Level 生物安全等級(jí) 2 

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. 

Product Format 提供形式 frozen 

Storage Conditions 保存方法 -80°C or colder

Preceptrol® no 

Annotated Genes AAC(1) AAC(6')-Ib7 acrB APH3-Ia APH(3'')-Ib APH(6)-Id cat catI CMY-16 macB mdtB mdtC mexB mexH mexI msbA TEM-2 tet(G) tet(J) VIM-1 

Type Strain 模式菌株 no 

Antibiotic Resistance The depositor states that this strain is ESBL negative. This has not been confirmed by ATCC. 

MIC Range Susceptible Amikacin: ≤16 μg/mL Aztreonam: ≤4 μg/mL Fosfomycin: ≤64 μg/mL Resistant Amoxicillin-clavulanate: ≥32/16 μg/mL Cefepime: ≥16 μg/mL Ceftazidime: ≥16 μg/mL Ceftriaxone: ≥4 μg/mL Ciprofloxacin: ≥4 μg/mL Doripenem: ≥4 μg/mL Imipenem: ≥4 μg/mL Levofloxacin: ≥8 μg/mL Meropenem: ≥4 μg/mL Piperacillin-tazobactam: ≥128/4 μg/mL Tetracycline: ≥16 μg/mL Trimethoprim-sulfamethoxazole: ≥4/76 μg/mL

Comments 注釋 This strain is part of the ATCC® Clinical 

Isolates Collection. It is an extensively characterized antimicrobial-resistant clinical isolate with validated genotypic and phenotypic activity against a variety of drug classes. 

This strain is provided with geographic source information; an NGS-assembled whole genome sequence, including annotated antibiotic resistance and rRNA genes; and an expanded level of susceptibility data with MIC test results. 

Minimum inhibitory concentration (MIC) ranges for resistant, intermediate, and susceptible are based on criteria within the Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, 26th Edition. 

Predicted antimicrobial resistance gene sequence data are provided for informational purposes only and are based on open reading frames (ORFs) identified and annotated from contigs produced during NextGen Sequencing (NGS). 

ATCC does not warrant that the entire predicted antimicrobial resistance gene is present within the sequence prepared for lot-specific reports. 

Likewise, the information provided merely indicates that some portion of the sequence (whole or in part) is present based on analytical base pair alignment with known gene sequences. 

Medium 培養(yǎng)基 ATCC® Medium 18: Trypticase Soy Agar/Broth 

Growth Conditions 生長(zhǎng)條件 

Temperature 培養(yǎng)溫度 : 37°C 

Atmosphere 需氧情況 : Aerobic

Name of Depositor 寄存人 International Health Management Associates (IHMA), Inc. 

Special Collection ATCC® Clinical Isolates Collection 

Chain of Custody 來(lái)源國(guó)家 ATCC <-- International Health Management Associates (IHMA), Inc. 

Isolation Urine 

Isolation 分離源 Date 2014 Geographic Source Greece Patient Age 50 Patient Gender Male 

References 參考文獻(xiàn) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 26th Edition. Wayne, PA. M100S, 2016.